Results 71 to 80 of about 15,810 (189)

A Meta-Analysis on Clinical Outcomes of Ceftolozane versus Piperacillin in Combination with Tazobactam in Patients with Complicated Urinary Tract Infections [PDF]

open access: yes, 2022
OBJECTIVE: To evaluate efficacy and adverse events of ceftolozane/tazobactam in complicated UTI including acute pyelonephritis. METHOD: Databases that include PubMed, Embase, Scopus, and TRIP were searched.
Vippadapu, Prasanna   +5 more
core   +1 more source

Broadly Defined Antibiotic Adjuvants for Pseudomonas aeruginosa

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, Volume 2026, Issue 1, 2026.
Pseudomonas aeruginosa is a widely distributed opportunistic pathogen with multiple drug resistance, making it particularly challenging to treat in lower respiratory tract infections. Its resistance mechanisms are complex, including low outer‐membrane permeability, efflux pump overexpression, biofilm formation, and quorum sensing (QS) activation ...
Zhihan Chen   +3 more
wiley   +1 more source

Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital [PDF]

open access: yes, 2019
Objectives. Our objective was to evaluate the in vitro activity of ceftolozane-tazobactam against multidrug resistant (MDR) and extensively drug-resistant (XDR) non metallo-ß-lactamase producing Pseudomonas aeruginosa clinical isolates at Hospital ...
Rezusta Lopez, Antonio   +8 more
core  

Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016–2018)

open access: yesInfection and Drug Resistance, 2022
Michael Pfaller,1,2 Dee Shortridge,1 Wei-Ting Chen,3 Helio Sader,1 Mariana Castanheira1 1JMI Laboratories, North Liberty, IA, USA; 2University of Iowa College of Medicine, Iowa City, IA, USA; 3Merck & Co., Inc, Kenilworth, NJ, USACorrespondence: Dee ...
Pfaller M   +4 more
doaj  

Case Report: Sepsis With Multisystemic Amyloid Light‐Chain Amyloidosis

open access: yesCase Reports in Critical Care, Volume 2026, Issue 1, 2026.
Introduction Systemic light‐chain (AL) amyloidosis is a complex disorder characterized by extracellular fibril deposition, leading to severe multisystem dysfunction. When sepsis superimposes on preexisting organ impairment, early clinical recognition becomes particularly challenging yet critical.
Mehtap Selçuk   +4 more
wiley   +1 more source

Ceftolozane–tazobactam in an elastomeric infusion device for ambulatory care: an in vitro stability study

open access: yes, 2019
Objectives: Published in vitro stability data for ceftolozane-tazobactam supports intermittent short duration infusions. This method of delivery is not feasible for many outpatient antimicrobial therapy services that provide only one or two visits per ...
Raby, Edward   +6 more
core   +1 more source

In Vivo Resistance to Ceftolozane/Tazobactam in Pseudomonas aeruginosa Arising by AmpC- and Non-AmpC-Mediated Pathways

open access: yesCase Reports in Infectious Diseases, 2018
Two pairs of ceftolozane/tazobactam susceptible/resistant P. aeruginosa were isolated from 2 patients after exposure to β-lactams. The genetic basis of ceftolozane/tazobactam resistance was evaluated, and β-lactam-resistant mechanisms were assessed by ...
Erik Skoglund   +11 more
doaj   +1 more source

Healthcare Resource Utilization of Ceftolozane/Tazobactam Versus Meropenem for Ventilated Nosocomial Pneumonia from the Randomized, Controlled, Double-Blind ASPECT-NP Trial

open access: yesInfectious Diseases and Therapy, 2020
Introduction Hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP) are associated with significant healthcare resource utilization (HCRU).
Thomas Lodise   +4 more
doaj   +1 more source

Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial

open access: yesAnnals of Intensive Care, 2023
Background The pivotal ASPECT-NP trial showed ceftolozane/tazobactam was non-inferior to meropenem for the treatment of ventilated hospital-acquired/ventilator-associated bacterial pneumonia (vHABP/VABP).
Ignacio Martin-Loeches   +8 more
doaj   +1 more source

Candidemia Complicated by Mycotic Thrombus of the Femoral Artery in a Patient With Left Ventricular Assist Device

open access: yesCase Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Background Ventricular assist devices (VADs) are increasingly used as a bridge to transplantation or as destination therapy in heart failure patients. Fungal bloodstream infections, though less common than bacterial infections in VAD recipients, carry the highest mortality.
Francesco Siviero   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy